Every Form 4 that BioLife Solutions Inc. (BLFS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BLFS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLFS filings page.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Marketing Officer Todd Berard had 470 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he holds 161,823 shares of common stock directly. No transactions were reported under a Rule 10b5-1 trading plan.
BIOLIFE SOLUTIONS INC (BLFS) executive Mathew Aby J., EVP & Chief Scientific Officer, had 564 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units, at a reference price of $36.69 per share. After this tax-withholding disposition, he holds 387,269 shares of BIOLIFE SOLUTIONS INC common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Technology Officer Sean Werner had 421 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units, at a value of $36.69 per share. After this tax-withholding disposition, he holds 47,135 shares of the company’s common stock directly, and no Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) director and President and CEO Roderick De Greef reported a Form 4 transaction involving company common stock. On September 18, 2026, 2,775 shares were withheld and disposed of to satisfy his tax withholding obligations arising from the release of restricted stock units, at a price of $36.69 per share. Following this tax-withholding transaction, he held 728,196 shares of common stock directly. No transactions were reported as made under a Rule 10b5-1 trading plan.
BIOLIFE SOLUTIONS INC (BLFS) reported that its Chief Financial Officer, Troy Wichterman, had 937 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he directly holds 211,286 shares of BLFS common stock.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Marketing Officer Todd Berard had 356 shares of common stock withheld on September 8, 2026 to satisfy his tax withholding obligations arising from the release of restricted stock units. The shares were withheld by the company rather than sold in the market, and Berard continues to hold 162,293 shares of BIOLIFE common stock directly after this tax-withholding disposition. No Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) reported that executive vice president and chief scientific officer Mathew Aby J. had 627 shares of common stock withheld on September 8, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. The shares were valued at $35.38 per share, and he now directly holds 387,833 shares of common stock. This was a tax-withholding disposition rather than an open-market sale, and no Rule 10b5-1 trading plan is reported.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Financial Officer Troy Wichterman had 1,026 shares of common stock withheld on September 8, 2026 to satisfy his tax withholding obligations arising from the release of restricted stock units. The shares were valued at $35.38 per share, and he now holds 212,223 shares directly. The transaction was a tax-withholding disposition, not an open-market sale, and no Rule 10b5-1 trading plan is reported.
BioLife Solutions Inc. Chief Technology Officer Sean Werner reported a tax-withholding disposition of 275 shares of Common Stock on July 17, 2026 at $29.15 per share. These shares were withheld by the company to satisfy Werner's tax obligations arising from the release of restricted stock units. After this withholding, Werner directly holds 47,556 shares of BioLife Solutions Common Stock.
BioLife Solutions’ Chief Financial Officer Troy Wichterman reported a Form 4 transaction involving 844 shares of common stock with a value of $27.79 per share. According to the disclosure, these shares were withheld by the company to satisfy tax withholding obligations arising from the release of restricted stock units, rather than sold in the open market. Following this tax-withholding disposition, Wichterman directly holds 213,249 shares of common stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported a tax-withholding disposition of 516 shares of common stock on July 7, 2026. The shares were withheld by the company to satisfy tax obligations upon the release of restricted stock units, and Aby now holds 388,460 shares directly.
BioLife Solutions Inc Chief Marketing Officer Todd Berard reported a tax-withholding disposition of 293 shares of Common Stock on 2026-07-07. The issuer withheld these shares to satisfy Berard’s tax obligations upon the release of restricted stock units at $27.79 per share, leaving him with 162,649 shares owned directly.
BioLife Solutions Chief Marketing Officer Todd Berard had 470 shares of common stock withheld by the company on the RSU vesting date to cover tax obligations. This was a tax-withholding disposition, not an open-market sale. After this withholding, he directly holds 162,942 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a small share disposition related to taxes, not an open-market trade. On the transaction date, 420 shares of Common Stock were withheld by the company at a price of $26.04 per share to cover tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, Werner held a remaining direct position of 47,831 Common Stock shares.
BioLife Solutions President and CEO Roderick De Greef reported a routine tax-related share withholding. The company withheld 2,775 shares of common stock to satisfy his tax obligations when restricted stock units were released. After this non-market transaction, he directly holds 730,971 shares of BioLife Solutions common stock.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 937 shares of Common Stock to cover his tax obligations at a value of $26.04 per share. After this withholding, Wichterman directly holds 214,093 shares of BioLife Solutions common stock, indicating that the event reflects compensation-related tax settlement rather than an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small share disposition tied to taxes rather than a market trade. On the release of restricted stock units, 564 shares of common stock were withheld by the company at $26.04 per share to satisfy his tax obligations. After this automatic tax-withholding event, he directly holds 388,976 shares of BIOLIFE SOLUTIONS INC common stock.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the reported date, 1,026 shares of common stock were withheld by the company to satisfy his tax withholding obligations arising from the release of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, Wichterman directly holds 215,030 shares of BioLife Solutions common stock, indicating he retains a substantial equity position. This filing reflects a compensation-related, non-discretionary transaction tied to vesting, not an active decision to buy or sell shares on the market.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported a routine tax-related share disposition. On the release of restricted stock units, 356 shares of Common Stock were withheld by the company to cover his tax withholding obligations. Following this, he directly holds 163,412 shares, so his overall stake remains largely unchanged and the transaction does not represent an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small, routine share disposition related to taxes. On June 8, 2026, 627 shares of common stock were withheld at $26.10 per share to satisfy tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, he directly held 389,540 shares of common stock.
BioLife Solutions Inc. reported insider activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. completed open-market sales totaling 1,200,000 shares of common stock over three days. The fund sold 300,000 shares at $22.65 on May 19, 2026, 250,000 shares at $23.70 on May 20, and 650,000 shares at $23.70 on May 21. After these sales, the Master Fund continued to hold 4,757,165 shares indirectly. According to the footnote, these securities are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.
BioLife Solutions EVP and Chief Scientific Officer Mathew Aby J. reported a small share disposition related to taxes, not an open-market trade. On the release of restricted stock units, 515 shares of common stock were withheld by the company at $19.27 per share to satisfy his tax obligations. After this tax-withholding event, he directly holds 390,167 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Marketing Officer Todd Berard reported a routine share disposition related to taxes. On the transaction date, 293 shares of common stock were withheld by the company to satisfy his tax withholding obligations that arose when restricted stock units were released. This was not an open-market sale. After this tax-withholding event, Berard directly held 163,768 shares of BIOLIFE SOLUTIONS INC common stock.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman had 844 shares of common stock withheld on April 8, 2026 to cover tax obligations from the release of restricted stock units. The shares were valued at $19.27 each, and he now directly holds 216,056 shares.
BioLife Solutions Inc. executive Karen A. Foster sold 2,577 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $19.17 per share and was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective December 4, 2025.
Following this transaction on March 23, 2026, Foster directly held 108,758 shares of BioLife Solutions common stock. The shares were sold in multiple trades at prices ranging from $18.99 to $19.35, and detailed breakdowns are available upon request as noted in the filing.
BioLife Solutions Inc. President and CEO Roderick De Greef had 11,101 shares of Common Stock withheld to cover taxes on restricted stock units that vested. These shares were delivered back to the company as a tax-withholding disposition, not sold on the open market. Following this transaction, he directly holds 733,746 shares of BioLife Solutions common stock.
BioLife Solutions Inc. reported an insider tax-withholding transaction by Chief Marketing Officer Todd Berard. On the release of restricted stock units, 1,879 shares of common stock were withheld by the company to cover his tax obligations. After this non-market disposition, Berard directly holds 164,061 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 1,681 shares of common stock at $19.12 per share to cover his tax obligations. After this withholding, Werner directly holds 48,251 shares of BIOLIFE SOLUTIONS common stock. This was not an open-market trade but an automatic share withholding mechanism tied to equity compensation.
BioLife Solutions Inc.'s Chief Financial Officer Troy Wichterman reported a routine tax-related share withholding tied to restricted stock vesting. On this Form 4, 3,749 shares of Common Stock were withheld at $19.12 per share to satisfy tax obligations that arose when restricted stock units were released.
These shares were not sold in the open market; they were retained by the company to cover taxes. After this transaction, Wichterman holds 216,900 shares of BioLife Solutions common stock directly, indicating he retains a substantial equity position following the RSU vesting event.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 931 shares of common stock to cover her tax obligations at $19.12 per share. After this withholding, she directly owns 92,429 shares. This was not an open-market sale but a standard mechanism tied to equity compensation vesting.
BioLife Solutions executive Karen A. Foster had shares withheld to cover taxes on equity compensation. On the release of restricted stock units, the company withheld 1,907 shares of Common Stock at a value of $19.12 per share to satisfy her tax obligations. After this tax-withholding disposition, she holds 111,335 shares of BioLife Solutions Common Stock directly.
BioLife Solutions EVP & Chief Scientific Officer Mathew Aby J. reported a routine tax-related share disposition. On the release of restricted stock units, 2,255 shares of common stock were withheld by the company at $19.12 per share to cover his tax obligations. After this withholding, he continues to directly own 390,682 shares of BioLife Solutions common stock, indicating that only a small portion of his overall holdings was affected and that this was not an open-market sale.
BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades. After these sales, she directly owns 113,242 shares.
BioLife Solutions Inc. reported that Chief Technology Officer Sean Werner executed an open-market sale of 111 shares of common stock on March 3, 2026 at $20.74 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan.
According to the filing, the trading plan, effective February 24, 2022, was established to satisfy tax withholding obligations arising from the vesting of restricted stock. After this sale, Werner directly holds 49,932 shares of BioLife Solutions common stock.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations, sold 418 shares of common stock in an open-market transaction at $20.74 per share. After this sale, she directly owned 210,665 shares. The sale was executed under a pre-established Rule 10b5-1(c) trading plan adopted to cover tax withholding tied to the vesting of restricted stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, sold 529 shares of common stock at $20.74 per share in an open‑market transaction. The sale was made under a Rule 10b5-1(c) trading plan adopted effective 02-24-2022 to cover tax withholding from vested restricted stock. After this sale, he directly held 392,937 common shares.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported an open-market sale of 588 shares of common stock at $20.74 per share. The transaction occurred on March 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan.
The footnote explains the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock. After this sale, Wichterman continues to hold 220,649 shares of BioLife Solutions common stock directly.
BioLife Solutions Inc. executive files small preplanned stock sale. Chief Human Resources Officer Sarah Aebersold sold 219 shares of common stock on March 3, 2026 in an open-market transaction at $20.74 per share. The sale was made under a Rule 10b5-1(c) trading plan adopted effective February 24, 2022 to satisfy tax withholding obligations from vested restricted stock. After this transaction, she directly holds 93,360 shares of BioLife Solutions common stock.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported an open-market sale of 353 shares of common stock at $20.74 per share on March 3, 2026. After this transaction, he directly held 165,940 shares of BioLife Solutions common stock.
According to the footnote, this sale was executed under a pre-established Rule 10b5-1(c) trading plan, adopted effective February 24, 2022. The plan was designed to satisfy tax withholding obligations related to the vesting of restricted stock, indicating the sale was part of a planned, tax-driven process rather than a discretionary trade.
BioLife Solutions Chief Marketing Officer Todd Berard reported equity compensation and related tax withholding in company stock. He received two grants of restricted common shares, one for 20,096 shares that vests 25% after one year and then in 12 quarterly installments, and another for 22,479 shares that vested at approximately 156% of the target grant based on the company’s total shareholder return versus selected peers from January 1, 2024 through December 31, 2025. In connection with the vesting of the market-based award, 8,846 shares were withheld at a price of $22.65 per share to cover tax obligations, leaving him with 166,293 common shares held directly after these transactions.
DuRoss Amy reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Amy DuRoss received an award of 8,170 shares of Common Stock as restricted stock. The grant was made at no cash cost under the BioLife Solutions 2023 Performance Incentive Plan and will fully vest on the first anniversary of the vesting date of January 2, 2026. After this award, DuRoss directly holds 26,857 common shares.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported equity compensation and related tax withholding transactions in company stock. On February 24, 2026, he acquired 31,150 shares and 64,866 shares of restricted common stock at $0 per share as grants under the 2023 Omnibus Performance Incentive Plan.
The first grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The second grant vested at approximately 156% of the target number of shares based on total shareholder return from January 1, 2024 through December 31, 2025 versus a peer group. To cover tax withholding on the vested market-based award, 25,525 shares were disposed of at $22.65 per share. Following these transactions, Wichterman directly held 221,237 shares of common stock.
Hunt Anthony reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Anthony Hunt received a grant of 8,170 shares of common stock as a restricted stock award. The award was made at no cash cost per share and increased his directly held common stock to 15,046 shares following the transaction. According to the footnote, the restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026."
Coste Catherine reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Catherine Coste reported an equity award of 8,170 shares of common stock as a grant under the BioLife Solutions 2023 Performance Incentive Plan. The restricted stock was granted at no cash price and will fully vest on the first anniversary of the vesting date of January 2, 2026. Following this award, Coste beneficially owns 13,871 common shares directly.
Ellingson Rachel reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Rachel Ellingson reported receiving a grant of 8,170 shares of restricted common stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These shares were granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the terms, fully vest on the first anniversary of the vesting date of January 2, 2026. Following this grant, Ellingson directly holds a total of 57,995 shares of BioLife Solutions common stock.
BioLife Solutions President and CEO Roderick De Greef reported several equity awards and related tax withholdings. On February 24, 2026, he acquired three blocks of restricted common stock totaling 118,730, 170,291 and 219,024 shares at a stated price of $0.00 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan, including 2026 compensation that vests 25% on the first anniversary and then in 12 equal quarterly installments. Other restricted stock vested based on total shareholder return from January 1, 2024 to December 31, 2025 versus peers and on specific performance metrics, leading to vesting at approximately 156% and 200% of target.
To satisfy tax withholding obligations on the market‑ and performance‑based vesting, 67,010 and 86,186 shares were disposed of at $22.65 per share through share withholding rather than open‑market sales. After these transactions, De Greef directly held 744,847 shares of BioLife Solutions common stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported equity awards and related share withholding in company stock. He acquired 20,096 shares of restricted common stock and 39,605 shares of market-based restricted stock on February 24, 2026 at a stated price of $0.0000 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan as part of 2026 compensation. One grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The market-based award vested at approximately 156% of the original grant based on relative total shareholder return versus selected peers from January 1, 2024 through December 31, 2025.
To cover tax withholding obligations on the vesting of the market-based award, 15,585 shares were withheld at $22.65 per share. Following these transactions, Mathew Aby J. directly owns 393,466 shares of BioLife Solutions common stock.
BioLife Solutions Chief Human Resources Officer Sarah Aebersold received a grant of 23,548 shares of common stock at $0.00 per share, tied to the company’s 2023 Omnibus Performance Incentive Plan. About 156% of the target shares vested based on relative total shareholder return, and 5,734 shares were withheld at $22.65 per share to cover taxes, leaving her with 93,579 shares directly owned.
Werner Sean reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Chief Technology Officer Sean Werner received a grant of 24,116 shares of common stock as part of his 2026 compensation. The restricted stock was issued under the 2023 Omnibus Performance Incentive Plan and will vest 25% on the first anniversary of the grant date, then in 12 equal quarterly installments. Following this award, he directly holds 50,043 shares of common stock.
MOORE TIMOTHY L. reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Timothy L. Moore received a grant of 8,170 shares of restricted common stock. The award was made at a stated price of $0.0000 per share and was granted under the BioLife Solutions 2023 Performance Incentive Plan.
According to the filing, these restricted shares will fully vest on the first anniversary of the vesting date of January 2, 2026. After this grant, Moore directly holds a total of 44,943 shares of BioLife Solutions common stock.